Dr. Shokeen’s lab has expertise in the development and evaluation of molecularly targeted small molecule and multi-functional macromolecular bio-conjugates for nuclear and optical imaging of cancer and cardiovascular diseases. Her group aspires to utilize the translational capabilities of quantitative imaging modalities (PET, SPECT, FMT and MRI) to bring the bench side discoveries into patient care. Working on the chemistry of imaging, the Shokeen lab has been evaluating high-affinity 64Cu labeled-Very Late Antigen-4 (VLA-4) targeted PET radiopharmaceuticals to assess disease progression and response to treatment in pre-clinical mouse and human models of multiple myeloma by quantitative receptor measurements. The ultimate goal of
these studies is successful clinical translation. Her group is also investigating the unique metabolic pathways and metabolite fate tracking in multiple myeloma tissues by using 13C edited 1H NMR and 11C-Acetate/PET-CT imaging. Additionally, as part of a multi-PI team, the Schokeen lab is developing a high-throughput optical in vivo imaging platform for the detection of unstable plaque in carotid arteries using a novel custom built Fluorescence Molecular Tomography (FMT) system.